Wird geladen...

Expanded use of rituximab in the management of non-Hodgkin lymphoma

Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemente...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Eichenauer, Dennis A, Engert, Andreas, Schulz, Holger
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2009
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2886316/
https://ncbi.nlm.nih.gov/pubmed/20616906
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!